October 18, 2005 -- Genentech reported that adding Tarceva to Avastin did not provide an benefit to kidney cancer patients; the FDA sent an approvable letter to Bristol-Myers Squibb and Merck for Pargluva, a drug aimed at type 2 diabetes; Kosan stopped a Phase II trial of KOS-862 for prostate cancer; Barr Pharma will acquire FEI Women’s Health LLC for $281.5 million; AlgoRx and Corgentech said their pain drug was effective against a foot ailment; and Lorus Therapeutics got cut in half after reporting that its pancreatic cancer drug failed a clinical trial. The Centient Biotech 200 closed 2 points lower at 3655, a drop of .06%.
